Navigation Links
Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference

e drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through the Company's website at www.lorusthera.com.

CONTACT: Lorus Therapeutics Inc., Dr. Saeid Babaei, (416) 798-1200 ext.490, ir@lorusthera.com

Ticker Symbol: (Toronto:LOR.),(AMEX:LRP)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

Post Your Comments:
(Date:11/27/2009)... -- At the upcoming Radiological Society of North ...al Philips Electronics ( PHG, AEX: PHI) will demon...matics solutions designed to directly address the ...vering meaningful imaging innovations that reflect... upgradability. This focus will enable Philips to...
(Date:11/25/2009)...RNewswire/ -- Praxis Electronic Medical Records re...y of Family Physicians, (AAFP) Family Practice Man...r improving medical quality, health maintenance, a...timulus legislation. Praxis also ranked #1 among d...in determining their salary. Finally, Praxis also ...
(Date:11/25/2009)...wswire-FirstCall/ -- Heska Corporation ( HSKA); ("...ic and specialty products to the veterinary indust...ics Corporation for the supply of blood gas produc...arket. ,, (Logo: http://www.newscom.com/cg...oche share the same passion for innovating in the ...
Breaking Medicine Technology:Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 1M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 2M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 3M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 4Will genomics help prevent the next pandemic 3F 60086 1Will genomics help prevent the next pandemic 3F 60086 2Will genomics help prevent the next pandemic 3F 60086 3Blue light filtering increases macular pigment may protect against age related vision loss 10527 1Blue light filtering increases macular pigment may protect against age related vision loss 10527 2Blue light filtering increases macular pigment may protect against age related vision loss 10527 3Blue light filtering increases macular pigment may protect against age related vision loss 10527 4
...ee of Four HUMIRA Patients from CHARM Study in Rem...mission at Two Years, ABBOTT PARK, Ill., May 21 ...Abbott pivotal studies, CHARM and GAIN,demonstrate...eated with,HUMIRA(R) (adalimumab) achieved long-te...ctively, according to data presentations today at ...
...nnovative pipeline products highlight Watson,s com...d Until 2:10 PM EDT, ORLANDO, Fla., May 21 Watso...ecialty pharmaceutical company, announced,today th...ase 3 products at,the American Urological Associat...iac safety trial involving silodosin, an investiga...
Other Medicine Technology:Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 2Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 4Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 5Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 6Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 7Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 2Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 3Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 4Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 5Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 6
(Date:11/29/2009)... "The YogaForce A-Lin..." says Dr. Andrew Weil, M.D., author and phys... the field of integrative medicine. Go to www.yo...itness minded on the gift list. , ...09 -- Just in time for the holidays, the YogaForce...
(Date:11/28/2009)...epeat offenders were more likely to consider chang... finds , , FRIDAY, Nov. 27 (HealthDay Ne...s to consider why they should stop their dangerous... changes, researchers have found. , The new stu...ving-while-impaired convictions, who were randomly...
(Date:11/27/2009)..., , KELOWNA, BC, Nov. 27 /PRNewswire/ - Uplo...ady seeing prime time in wellness. A combination o...ed data upload are solving a long term concern ove...sible to accurately gauge and reward improved part...echnologies is one of the first wellness suppliers...
(Date:11/27/2009)..., , ROCHESTER, N.Y., Nov. 27 /PRNewswire-US...ry health care provider and fortunately every year...e prevention. But do all vaccines boost immunity f...additional ,booster shots, needed to keep immunity...cs, the Journal of the American Academy of Pediatr...
(Date:11/27/2009)...alking and cycling plus low-emission vehicles may ... , FRIDAY, Nov. 27 (HealthDay News) -- Enco...of using cars would offer much greater public heal...hicles, U.K. researchers have found. , The stud... alternative urban land transport scenarios for Lo...
Breaking Medicine News(10 mins):Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 3Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:More Foot Power, Less Car Pollution Best for Health 2
...INGTON, Feb. 18 Judie Brown, president of Americ...ifical Academy for Life, issued the followin...dict XVI and U.S. House of Representatives Spe...nt regarding the requirements of moral law. The Va...
...OWN, Pa., Feb. 18 Grounded in science and inspire...up of independent but complementary medical commun...ality, scientific programs that educate, motivate,...ns, quality execution, business integrity, and res...
...LOUIS, Feb. 18 Spurred by seizures of vital docto...e pharmacies in Australia and New Zealand to U.S. ...s today called for President Obama to order the Fo...e publishers are Frank Kaiser, of www.SuddenlySen...
...LONGJUMEAU, France, February 18 , - Sales Affec..., - Operating Profitability Has Resisted Well, ...ns of euros 2008 2007, Net ... 14.5%, Current operating income* ...
...hwestern Mutual releases research revealing stark ... living facilities and nursing homes across the U....nding nearly seven times more for certain long-ter... home health care providers, assisted living facil...
... Outgoing Cabinet Head and For...utives With Washington Insider,s View on Healthcar...ocus) February 18, 2009 -- ConnextionsHealth annou...Utah (1993-2003) - will address the World Congress...
Other Medicine News:Health News:Pope to Pelosi: Catholic Politicians Must Protect Life 2Health News:CONNEXION Healthcare Announces New Hires for 2009 2Health News:Seniors' Website Publishers Ask President to Curtail FDA Seizures of Vital Medicines 2Health News:PCAS: 2008 Results 2Health News:PCAS: 2008 Results 3Health News:Location, Location, Location: Cost of Long-Term Care Services Vary Widely by Region 2Health News:Location, Location, Location: Cost of Long-Term Care Services Vary Widely by Region 3Health News:Former Health & Human Services Secretary Michael Leavitt To Address Health Plan Member Retention Summit 2Health News:Former Health & Human Services Secretary Michael Leavitt To Address Health Plan Member Retention Summit 3
...tric based optical detection system which measures...ght transmittance. The system consists of an instr... assay device contains reagents based on microbead...ns a lyophilized preparation of human fibrinogen-c...
DLP® Multiple Perfusion Sets
DLP Pediatric Aortic Root Cannulae
Gundry® RCSP Cannulae
Medicine Products: